Thanks to funding from Proposition 71, California’s $3 billion investment in stem cell research, and the state funding entity it created, the California Institute for Regenerative Medicine (CIRM), there are now 36 human clinical trials in various stages of progress, including a trial for HIV/AIDS.
Accepting Applicants: No
Status: Phases 1/2 trial in progress
Description: Clinical trial of stem cell gene therapy for HIV/AIDS
CIRM Funding Brief: “The Calimmune team is using a method called RNA interference to block the CCR5 gene from generating a protein. A blood system generated from these cells will lack CCR5 and block HIV infection. The team has begun a clinical trial with the procedure.” Read more at CIRM.
Current Sponsor: Calimmune, Inc.
Principal Investigator: Ronald Mitsuyasu, MD
Institution: University of California, Los Angeles
Phase 1/2 Filed: N/A
Phase 1/2 Approved: N/A
Cell Therapy Type: N/A
NCT No. / Link: NCT01734850
Completion Date: Projected June 2017
Last Updated: November 28, 2016
As this clinical trial moves forward, we will update this page. Check back here for future developments.
As scientists and patient advocates build on the progress that Proposition 71 has enabled, we must keep the momentum going, understanding that there is still much work to be done. We must remember that human trials will celebrate successes; but, barriers will surface, along with complications and challenges, so patience and understanding of the scientific discovery process is essential. Even the setbacks will provide critical knowledge that will bring us closer to curing or mitigating devastating diseases and injuries. Only with continued support for biomedical research can we increase our understanding of the therapeutic potential of stem cells, and translate that understanding into meaningful treatments that help give patients their lives back.